BR112019024742A2 - Proteínas robo2 recombinantes, composições, métodos e usos das mesmas - Google Patents

Proteínas robo2 recombinantes, composições, métodos e usos das mesmas

Info

Publication number
BR112019024742A2
BR112019024742A2 BR112019024742-4A BR112019024742A BR112019024742A2 BR 112019024742 A2 BR112019024742 A2 BR 112019024742A2 BR 112019024742 A BR112019024742 A BR 112019024742A BR 112019024742 A2 BR112019024742 A2 BR 112019024742A2
Authority
BR
Brazil
Prior art keywords
methods
compositions
same
recombinant
proteins
Prior art date
Application number
BR112019024742-4A
Other languages
English (en)
Inventor
Berasi Stephen
Elizabeth Buhlmann Janet
Higginson-Scott Nathan
Shamashkin Michael
Russo Matthew
V. GULLA Stefano
Sean Juo Zong
R. KODANGATTIL Sreekumar
Lu Weining
Fan Xueping
J. Salant David
Original Assignee
Pfizer Inc.
Boston Medical Center Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc., Boston Medical Center Corporation filed Critical Pfizer Inc.
Publication of BR112019024742A2 publication Critical patent/BR112019024742A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Abstract

a presente invenção refere-se a proteínas recombinantes do receptor 2 roundabout (robo2) projetados para ligar os ligantes de slit e evitar a sua ligação aos receptores de superfície celular robo2. também são fornecidos métodos para o uso dessas proteínas recombinantes robo2.
BR112019024742-4A 2017-06-02 2018-05-31 Proteínas robo2 recombinantes, composições, métodos e usos das mesmas BR112019024742A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762514242P 2017-06-02 2017-06-02
US62/514,242 2017-06-02
US201862663082P 2018-04-26 2018-04-26
US62/663,082 2018-04-26
PCT/US2018/035361 WO2018222850A1 (en) 2017-06-02 2018-05-31 Recombinant robo2 proteins, compositions, methods and uses thereof

Publications (1)

Publication Number Publication Date
BR112019024742A2 true BR112019024742A2 (pt) 2020-06-16

Family

ID=62784223

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019024742-4A BR112019024742A2 (pt) 2017-06-02 2018-05-31 Proteínas robo2 recombinantes, composições, métodos e usos das mesmas

Country Status (16)

Country Link
US (1) US10906955B2 (pt)
EP (1) EP3630808A1 (pt)
JP (2) JP7018458B2 (pt)
KR (1) KR20200016292A (pt)
CN (1) CN110709415A (pt)
AU (2) AU2018278809B2 (pt)
BR (1) BR112019024742A2 (pt)
CA (1) CA3006926A1 (pt)
CO (1) CO2019013315A2 (pt)
IL (1) IL270917A (pt)
MX (1) MX2019014480A (pt)
PE (1) PE20200495A1 (pt)
PH (1) PH12019502717A1 (pt)
SG (1) SG10201913194WA (pt)
TW (1) TW201902920A (pt)
WO (1) WO2018222850A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112195154B (zh) * 2019-07-08 2024-03-29 江苏汇智生物科技有限公司 一种基因改造表达改造型pla2r受体的细胞及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
DE69816467T2 (de) 1997-10-20 2004-04-15 The Regents Of The University Of California, Oakland Robo: eine familie polypeptiden und nukleinesäuren wirksam in nervenzellleitung
WO2003075860A2 (en) 2002-03-08 2003-09-18 Abgent, Inc. Detection and modulation of slit and roundabount (robo) mediated angiogenesis and uses thereof
WO2005063815A2 (en) 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
BRPI0806403A2 (pt) * 2007-02-09 2011-09-06 Genentech Inc anticorpo anti-robo4, usode um anticorpo e método de obtenção de imagem
FR2958936A1 (fr) 2010-04-14 2011-10-21 Sanofi Aventis Proteine de fusion robo1-fc et son utilisation dans le traitement des tumeurs
JP2014507395A (ja) * 2010-12-23 2014-03-27 サノフイ 肝癌の治療における使用のためのＲｏｂｏ１−Ｆｃ融合タンパク質
SG11201403746SA (en) * 2012-01-05 2014-07-30 Boston Medical Ct Corp Slit-robo signaling for diagnosis and treatment of kidney disease
JP2013230115A (ja) * 2012-04-27 2013-11-14 Daiichi Sankyo Co Ltd 抗ｒｏｂｏ４抗体
EP3156074B1 (en) * 2012-06-15 2019-06-05 The Asan Foundation Composition for preventing or treating fracture or osteoporosis using slit-robo system
ES2962694T3 (es) * 2014-05-02 2024-03-20 Momenta Pharmaceuticals Inc Composiciones y procedimientos relacionados con construcciones de Fc manipuladas
US9884921B2 (en) * 2014-07-01 2018-02-06 Pfizer Inc. Bispecific heterodimeric diabodies and uses thereof
US20180282410A1 (en) * 2015-10-02 2018-10-04 Hoffmann-La Roche Inc. Anti-cd3xrob04 bispecific t cell activating antigen binding molecules

Also Published As

Publication number Publication date
RU2019143457A (ru) 2021-07-09
AU2018278809B2 (en) 2022-03-31
CA3006926A1 (en) 2018-12-02
JP7315637B2 (ja) 2023-07-26
AU2022204368A1 (en) 2022-07-14
CN110709415A (zh) 2020-01-17
WO2018222850A1 (en) 2018-12-06
TW201902920A (zh) 2019-01-16
MX2019014480A (es) 2020-01-23
AU2018278809A1 (en) 2019-11-21
US20180346542A1 (en) 2018-12-06
PE20200495A1 (es) 2020-03-04
PH12019502717A1 (en) 2020-10-19
JP7018458B2 (ja) 2022-02-10
RU2019143457A3 (pt) 2021-11-02
US10906955B2 (en) 2021-02-02
WO2018222850A8 (en) 2019-11-21
SG10201913194WA (en) 2020-03-30
JP2022033727A (ja) 2022-03-02
IL270917A (en) 2020-01-30
EP3630808A1 (en) 2020-04-08
KR20200016292A (ko) 2020-02-14
US20210214414A1 (en) 2021-07-15
CO2019013315A2 (es) 2020-04-01
JP2020522248A (ja) 2020-07-30

Similar Documents

Publication Publication Date Title
PH12018501882A1 (en) Binding proteins and methods of use thereof
CO2018011668A2 (es) Neoantígenos y métodos de su uso
BR112018073761A2 (pt) proteínas de ligação ao cd3 de fragmento variável de cadeia única
BR112018070260A2 (pt) receptores quiméricos e métodos de uso dos mesmos
EA201890866A1 (ru) Связывающие молекулы, которые ингибируют рост рака
BR112018068703A2 (pt) inibidores substituídos de menin-mll e métodos de uso
BR112018072946A2 (pt) proteínas de fusão a gdf15 e usos das mesmas
CO2018013471A2 (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y fármaco
CO2019002609A2 (es) Proteínas de unión recombinantes y sus usos
BR112019007100A2 (pt) composições e métodos para reprogramação de receptores de célula t com o uso de proteínas de fusão
CL2023000896A1 (es) Receptores quiméricos de dll3 y métodos para su uso
BR112018002844A2 (pt) receptores de antígeno quimérico à base de anticorpos de domínio único e métodos de uso dos mesmos
BR112018068189A2 (pt) proteínas de ligação induzíveis e métodos de uso
MX2021009352A (es) Compuestos de fijacion al receptor de il -2.
BR112019012343A2 (pt) anticorpos il-11ra
EA201991168A1 (ru) Белок, связывающий простатический специфический мембранный антиген
EA201990017A1 (ru) Антитела к миостатину и способы их применения
BR112018005573A2 (pt) ?polipeptídeos de ligação a cd3?
BR112019023071A2 (pt) proteínas de fusão do receptor tgf-beta do tipo ii e uso das mesmas
BR112015022260A2 (pt) anticorpo monoclonal, polinucleotídeo, composição farmacêutica, fragmento isolado de tau, uso de um anticorpo, método de triagem de um agente e ácido nucleico
BR112018075653A2 (pt) anticorpos anti-b7-h3 e conjugados anticorpo fármaco
BR112018075649A2 (pt) anticorpos anti-b7-h3 e conjugados de fármaco de anticorpo
EA201792466A1 (ru) АНТИТЕЛА ПРОТИВ FcRn
EP3543335A3 (en) Soluble intein fusion proteins and methods for purifying biomolecules
EA201691691A1 (ru) Белки слияния tatk-cdkl5, их композиции, составы и применение

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B25G Requested change of headquarter approved

Owner name: BOSTON MEDICAL CENTER CORPORATION (US) ; PFIZER INC. (US)